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Abstract Extracellular diadenosine polyphosphates (ApnA),
through their interactions with appropriate P2 receptors,
influence a diverse range of intracellular activities. In particular,
Ap4A stimulates alterations in intracellular calcium homeostasis
and subsequent activation of glycogen breakdown in isolated liver
cells. Here we show that, like ATP, Ap4A and other naturally
occurring diadenosine polyphosphates attenuate glucagon-stimu-
lated accumulation of cyclic AMP in isolated rat liver cells. The
characteristics of Ap4A- and ATP-dependent modulation of
glucagon-stimulated cyclic AMP accumulation are similar.
These results are discussed in the context of the repertoire of
intracellular signalling processes modulated by extracellular
nucleotides.
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1. Introduction
Diadenosine polyphosphates (ApnA; where n = 3, 4, 5 or 6)
have been identi¢ed in a wide variety of cells [1]. In mamma-
lian cells they account for a signi¢cant proportion of the nu-
cleotide content of a variety of storage granules including
dense granules of platelets [2], secretory granules of chromaf-
¢n cells [3] and neuronal synaptic vesicles [4]. Liberation into
the extracellular environment allows diadenosine polyphos-
phates to exert e¡ects on a diverse range of target cells [5].
Compared to ATP, the diadenosine polyphosphates are char-
acterised in vivo by relatively long half-lives and may there-
fore be suited to a role as long-range signalling molecules,
exerting e¡ects on target cells relatively distant from the site
of their release into the extracellular space [2].
Diadenosine polyphosphates promote signi¢cant alterations
in liver cell metabolism. Both Ap3A and Ap4A cause a tran-
sient release of CA2 and stimulation of glucose output from
the perfused rat liver [6]. In isolated rat liver cells, these ef-
fectors promote dose-dependent stimulation of glycogen phos-
phorylase activity [7] and oscillations in cytosolic free [Ca2]
that resemble those seen in liver cells exposed to ATP or ADP
[8]. An analysis of the characteristics of the binding of Ap4A
to rat liver cell membranes suggests that it exerts its e¡ects
through interaction with P2Y-like purinoceptor population [9].
In addition to their well characterised e¡ects on intracellu-
lar calcium metabolism, extracellular adenine mononucleoti-
des (e.g. ATP), like many other Ca2-mobilising agents, in£u-
ence cyclic AMP metabolism. Speci¢cally, ATP attenuates the
impact of both forskolin and glucagon on cyclic AMP accu-
mulation in isolated liver cells [10,11]. These e¡ects have been
ascribed to mononucleotide-mediated stimulation of phospho-
diesterase activity and/or inhibition of adenylate cyclase activ-
ity. Analogous e¡ects of extracellular adenine mononucleoti-
des have been observed in relation to agonist-stimulated cyclic
AMP accumulation in a range of di¡erent cell types (e.g.
isoproterenol-treated C6 glial cells [12] ; PGE1-treated
NG108-15 and NIE-115 neural cells [13]). It has also been
suggested that exposure of isolated liver cells to Ap3A and
Ap4A may also result in a diminution of glucagon-mediated
cyclic AMP accumulation [14]. In contrast, in other cell types
extracellular ATP stimulates cyclic AMP accumulation (e.g.
MDCK epithelial cells [15] and mouse C2C12 myotubes [16]).
Here we describe an analysis of the e¡ects of extracellular
diadenosine polyphosphates on intracellular cyclic AMP con-
centrations in isolated rat liver cells. The purpose of this in-
vestigation was to provide a better understanding of the over-
all impact of these unusual nucleotides on intracellular
signalling processes and also to provide information on the
nature of the relationship between diadenosine polyphos-
phate- and mononucleotide-mediated intracellular signalling
processes in rat liver cells.
2. Materials and methods
2.1. Chemicals
All nucleotides and cyclic AMP-dependent protein kinase (from
porcine heart) were obtained from Sigma, Poole, Dorset, UK. Colla-
genase and fatty acid-free bovine serum albumin were from Boeh-
ringer (London), Lewes, Sussex, UK. [8-3H]Adenosine-3P,5P-cyclic
phosphate ([3H]cyclic AMP; 23 Ci/mmol) was obtained from Amer-
sham International, Amersham, Bucks, UK. Optiphase Safe scintilla-
tion £uid was from Pharmacia-LKB Biotechnology, Milton Keynes,
UK. All other chemicals were of the purest grade available from
standard suppliers.
2.2. Animals
Male Wistar rats (University of Liverpool breeding colony) weigh-
ing 180^220 g were used throughout. Animals were fed ad libitum
(Labsure Animal diet (CRM); C. Hill Group, Poole, Dorset, UK).
2.3. Preparation and incubation of isolated rat liver cells
Liver cells were prepared as described previously [17]. Cells were
incubated at 37‡C in Krebs-Henseleit medium [18]. In all cases, the
incubation medium was supplemented with 2.5 mM CaCl2, 2% (w/v)
fatty acid-free bovine serum albumin, lactate/pyruvate (9:1; ¢nal
conc. 10 mM) and 10 mM glucose, Incubation volumes were 0.4 ml
throughout. Incubations were terminated by addition of 0.04 ml of
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2 M HClO4. Acidi¢ed suspensions were centrifuged at 12 000Ug for
2 min at 4‡C to remove denatured protein. Portions of supernatant
were then neutralised with 0.5 M triethanolamine/HCl containing 2 M
KOH. After storage on ice, neutralised samples were centrifuged at
12 000Ug for 2 min at 4‡C (to remove KClO4) and supernatants were
retained for determination of cyclic AMP concentrations. In all ex-
periments, metabolic integrity was assessed by measurement of the
cellular ATP content [19].
2.4. Measurement of cyclic AMP concentrations
Samples from isolated liver cell incubations, prepared as described
above, were utilised for assay of cyclic AMP concentrations essentially
as described previously [20]. Brie£y, the assay depended upon the
displacement, by unlabelled cyclic AMP, of [3H]cyclic AMP from
the cyclic AMP-dependent protein kinase. Construction of a standard
curve, prepared by addition of known amounts of unlabelled cyclic
AMP (0^25 pmol) to neutralised, perchloric acid-treated incubation
bu¡er (see above), allowed the estimation of the cyclic AMP content
of neutralised liver cell extracts.
3. Results
Incubation of isolated liver cells in the presence of extra-
cellular ATP or Ap4A did not result in signi¢cant alterations
in the basal intracellular cyclic AMP concentration (Table 1).
In contrast, when the intracellular cyclic AMP concentration
was elevated, by exposure of liver cells to a physiological
concentration of glucagon, both ATP and Ap4A were able
to signi¢cantly attenuate this change. Fig. 1 shows time
courses for glucagon-induced cyclic AMP concentration
changes in the absence and presence of these nucleotides. It
is clear from these data that ATP and Ap4A are similarly
e¡ective in attenuating the glucagon-mediated increase in
cyclic AMP concentration. Both e¡ectors act rapidly
(6 1 min) to decrease the change in glucagon-stimulated
cyclic AMP accumulation. It should be noted that over this
time course, under these incubation conditions, signi¢cant
degradation of the Ap4A does not occur [7] implying that it
is the intact nucleotide that is directly responsible for the
observed e¡ects.
Fig. 2 shows the e¡ect of variation in nucleotide concen-
tration on the accumulation of cyclic AMP observed in re-
sponse to a physiological concentration of glucagon. Attenu-
ation of cyclic AMP accumulation was apparent at
concentrations of Ap4A (and ATP) 6 100 WM. Given that
Ap4A concentrations in vivo have been estimated to reach
10^100 WM [2], it would appear that the attenuation of hor-
mone-stimulated increases in liver cell cyclic AMP concentra-
tion is, potentially, a signi¢cant aspect of the intracellular
signalling processes triggered by this agent. Fig. 3 shows the
impact of Ap4A and ATP on the accumulation of cyclic AMP
brought about by di¡erent concentrations of glucagon. These
data indicate that both nucleotides are potent attenuators of
the cyclic AMP accumulation induced by concentrations of
glucagon within the physiological range. Taken together the
data in Figs. 2 and 3 suggest that the ability of Ap4A to
diminish glucagon-stimulated increases in cyclic AMP concen-
trations is of physiological signi¢cance; additionally, the char-
acteristics of this e¡ect are essentially similar for both ATP
and Ap4A. However, in view of the relative stabilities of ATP
and Ap4A in the extracellular environment (see Section 1), it
might be anticipated that Ap4A is the more e¡ective agent, if
released from a site relatively distant from the target tissue
(i.e. liver).
In addition Ap4A, both higher and lower homologues are
also present in mammalian tissues. The ability of a range of
diadenosine polyphosphates to modulate glucagon-stimulated
Table 1
The e¡ect of di¡erent nucleotides on intracellular cyclic AMP con-
centration in isolated liver cells
Incubation condition [cyclic AMP] after 1 min incubation
(pmol/mg dry weight)
Basal 1.59 þ 0.38
1 mM ATP 2.97 þ 0.90
1 mM Ap4A 1.67 þ 0.48
1 nM Glucagon 13.61 þ 1.46*
1 nM Glucagon+1 mM ATP 6.25 þ 0.74*2
1 nM Glucagon+1 mM Ap4A 5.36 þ 0.99*2
Results are expressed as means þ S.E.M. for at least three independ-
ent liver cell incubations. The signi¢cance of di¡erence between
means was assessed by Student’s t-test. *P6 0.05, versus basal con-
dition; 2P6 0.05, for glucagon and the indicated nucleotide versus
glucagon only. Other di¡erences were not signi¢cant.
Fig. 1. Time course of cyclic AMP accumulation following exposure
of isolated liver cells to glucagon (10 nM), either alone (b) or in the
presence of 100 WM ATP (F) or 100 WM Ap4A (a). Results are the
means of triplicate values from a single representative experiment.
Fig. 2. Dose-dependent e¡ect of ATP (F) or Ap4A (b) on 10 nM
glucagon-stimulated cyclic AMP accumulation in isolated liver cells,
after 1 min incubation. Results are expressed as means þ S.E.M. for
at least three independent liver cell incubations. The signi¢cance of
di¡erence between means was assessed by Student’s t-test.
*P6 0.05, for glucagon and the indicated nucleotide versus gluca-
gon only. Other di¡erences were not signi¢cant.
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cyclic AMP accumulation in isolated liver cells is illustrated in
Table 2. It is clear from these data that the other diadenosine
polyphosphates are also e¡ective attenuators of glucagon-
stimulated cyclic AMP accumulation. The only exception is
the synthetic nucleotide Ap2A which appears to be without
e¡ect. This parallels the inability of Ap2A to displace
[3H]Ap4A from hepatic purinoceptors [9]. It is also of interest
that, whereas UTP is an e¡ective attenuator of cyclic AMP
accumulation [11], 2-methylthioadenosine 5P-triphosphate
(2MeSATP) is ine¡ective [21]. We have previously observed
that both UTP and 2MeSATP displace [3H]-Ap4A from hep-
atic purinoceptors [9], indicative of the presence of a mixed
population of P2Y-purinergic receptors responsible for binding
Ap4A (i.e. P2Y1 and P2Y2). Consequently, it would appear that
the ability of the diadenosine polyphosphates to attenuate
glucagon-induced cyclic AMP accumulation may be mediated
by UTP-(P2Y2) rather than 2MeSATP-(P2Y1) recognising re-
ceptors.
4. Discussion
Here we have presented evidence that the diadenosine poly-
phosphates are capable of modulation of cyclic AMP accu-
mulation mediated by physiological concentrations of gluca-
gon. The characteristics of Ap4A-mediated attenuation of
cyclic AMP accumulation are essentially similar to those ex-
hibited by ATP. It is not clear from the present data if this
attenuation is a consequence of inhibition of adenylate cyclase
activity and/or stimulation of cyclic AMP phosphodiesterase
activity. It has been suggested that ATP-dependent inhibition
of adenylate cyclase activity may be mediated by phosphatidic
acid, arising from the hydrolysis of phosphatidyl-choline by
phospholipase D [22,23]. In this context it is of interest that
we have recently demonstrated that the diadenosine polyphos-
phates are capable of activating phospholipase D in isolated
rat liver cells [24] ; however, it should also be pointed out that
UTP, an e¡ective attenuator of agonist-stimulated cyclic
AMP accumulation (see Table 2), is a relatively weak stimu-
lator of phospholipase D activation [24].
Given the widespread occurrence of ‘crosstalk’ between in-
tracellular signalling pathways, it is perhaps not surprising
that the diadenosine polyphosphates, like other nucleotides,
are capable of modulating the accumulation in cyclic AMP
mediated by agonists such as glucagon. Likewise, it would not
be surprising if alterations in cyclic AMP metabolism led to
changes in the ability of the diadenosine polyphosphates to
stimulate oscillations in liver cell cytosolic free [Ca2]. In this
respect, recent work has con¢rmed that this is the case for
cytosolic free [Ca2] oscillations induced by ATP and ADP
[25] and also for diadenosine polyphosphate-stimulated oscil-
lations in cytosolic free [Ca2] [26].
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